ArticleClinical reviews in allergy & immunology2008
Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis.
Article in Clinical reviews in allergy & immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03224377 (Diagnostic Utility of Anti-mutated Citrullinated Vimentin Antibodies,Anti Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnostic Utility of Anti-mutated Citrullinated Vimentin Antibodies,Anti Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis.Rheumatology international · 2011Pooled it
- Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.Clinical rheumatology · 2010Pooled it
- Diagnostic utility and clinical relevance of anti-MCV and anti-CCP antibodies in rheumatoid arthritis.Clinical and experimental medicine · 2025Article
- Exploring Anticitrullinated Antibodies (ACPAs) and Serum-Derived Exosomes Cargoes.Antibodies (Basel, Switzerland) · 2025Article
- Deciphering the therapeutic potential of trimetazidine in rheumatoid arthritisFrontiers in pharmacology · 2024Article
- Anti-vimentin antibodies are associated with higher severity of Sjögren's disease.Clinical immunology (Orlando, Fla.) · 2023Article
- Anti-mutated citrulline vimentin antibodies may be higher in Ankylosing spondylitis, but may not have a role in diagnosing disease and may not be associated with disease severity.Northern clinics of Istanbul · 2023Article
- 2D-DIGE-Based Proteomic Profiling with Validations Identifies Vimentin as a Secretory Biomarker Useful for Early Detection and Poor Prognosis in Oral Cancers.Journal of oncology · 2022Article
- Immune cells in lens injury repair and fibrosis.Experimental eye research · 2021Review
- Characterizing hand and wrist ultrasound pattern in primary Sjögren's syndrome: a case-control study.Clinical rheumatology · 2020Article
- Vimentin Diversity in Health and Disease.Cells · 2018Review
- Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis.Journal of immunology research · 2014Article
- Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing.BioMed research international · 2014Article
- Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?BMC medicine · 2013Review
- Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach.PloS one · 2013Article
- Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families.The Korean journal of internal medicine · 2013Article
- Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.Rheumatology international · 2012Article
- Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated Peptide antibodies and rheumatoid factor in omani patients with rheumatoid arthritis.International journal of rheumatology · 2012Article
- The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.Rheumatology (Oxford, England) · 2011Review
- Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis.Archives of medical science : AMS · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe last 5 years have seen the emergence and establishment of antibodies to citrullinated antigens as the diagnostic marker for rheumatoid arthritis (RA). Initially, these were detected using a synthetic peptide, which has undergone a number of modifications to give a diagnostic test with a sensitivity of 65-80% and a specificity of >95%. Antibodies to citrullinated vimentin were first described in 1994 as a highly specific marker for RA (anti-Sa). However, no easily performed assay for these antibodies has been available.
methodsWe have examined the use of a ELISA-based assay with a mutated citrullinated vimentin (MCV) antigen (Orgentec, Mainz, Germany) to assess the diagnostic and prognostic utility of this antibody in RA.
resultsAntibodies to MCV were detected in the sera of 74% RA patients (specificity 96%), 2% systemic lupus erythematosus, 14% Sjögren's syndrome, and 2% scleroderma. Anti-MCV was not detected in sera from healthy blood donors. There was no difference in the frequency of antibodies detected in RA patients with early (<2 years) or chronic (>2 years) disease. There was no significant variation in anti-MCV antibody concentrations in early RA patients over a 52-week period. No significant change was observed with time between the two treatment groups of methotrexate alone or methotrexate plus infliximab.
conclusionsAntibodies to MCV are a specific and sensitive marker for the diagnosis of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.